Contemporary Detection Of 4-Demeth-Oxydaunorubicin And Its Metabolites 13-Dihydro-4-Demethoxydaunorubicin And4-Demethoxydaunorubicinone By Reverse Phase High-Performance Liquid Chromatography
暂无分享,去创建一个
[1] J. Kovach,et al. Dose-dependent pharmacokinetics and cancer chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.
[2] C. Hackmann. Experimentelle Untersuchungen über die Wirkung von Actinomycin C (HBF 386) bei bösartigen Geschwülsten , 1952, Zeitschrift für Krebsforschung.
[3] B. Leyland-Jones,et al. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. , 1985, Cancer research.
[4] V. Bellotti,et al. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. , 1983, Journal of chromatography.
[5] M. Ranghieri,et al. Determination of 4'-epidoxorubicin and its 13-dihydro derivative in human plasma by high-performance liquid chromatography with fluorescence detection. , 1982, Journal of chromatography.
[6] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[7] R. Weiss,et al. Daunorubicin treatment of adult solid tumors. , 1981, Cancer treatment reports.
[8] S. Eksborg,et al. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. , 1979, Journal of chromatography.
[9] D. Henry,et al. Synthesis of daunorubicin analogues with novel 9-acyl substituents. , 1979, Journal of medicinal chemistry.
[10] S. Eksborg,et al. Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. , 1978, Journal of chromatography.
[11] F. Arcamone,et al. Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin. , 1978, Cancer treatment reports.
[12] S. Eksborg. Reversed-phase liquid chromatography of adriamycin and daunorubicin and their hydroxyl metabolites adriamycinol and daunorubicinol. , 1978, Journal of chromatography.
[13] R. Gale,et al. HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIA , 1977, The Lancet.
[14] J. A. Page,et al. Cardiotoxicity of adriamycin and related anthracyclines. , 1976, Cancer treatment reviews.
[15] N. Bachur. Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes. , 1976, Science.
[16] S. Carter. Adriamycin-a review. , 1975, Journal of the National Cancer Institute.
[17] F. Formelli,et al. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. , 1975, Journal of medicinal chemistry.
[18] E. Herman,et al. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943). , 1974, Toxicology and applied pharmacology.
[19] A. Di Marco,et al. Cytotoxic, antiviral, and antitumor activity of some derivatives of daunomycin (NSC-82151). , 1973, Cancer chemotherapy reports.
[20] E. Herman,et al. THE POSSIBLE RELATIONSHIP BETWEEN METABOLISM AND CARDIAC TOXICITY OF DAUNOMYCIN AND RELATED COMPOUNDS , 1971 .
[21] K. Conklin,et al. Chlorpromazine effects on macromolecular syntheses in synchronized tetrahymena. , 1971, Pharmacology.
[22] E. Preiskel. Peptic oesophageal ulcer; nonfatal perforation. , 1946, Lancet.